News Release


 View printer-friendly version

« Back

Rigel to Host Investor & Analyst Day in New York City on October 4, 2018

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) today announced that it will host an investor and analyst day event on Thursday, October 4, 2018 from 12:00pm to 2:30pm Eastern Time in New York City. Members of Rigel's management team and leading clinical experts will provide updates on the company's recent launch of TAVALISSETM, development program for fostamatinib in the treatment of autoimmune hemolytic anemia, and strategy for pipeline expansion.

The event will feature presentations from Dr. David Kuter, Director of Clinical Hematology at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School; and Dr. Amit Mehta, Board-Certified Hematologist and Medical Oncologist at Premier Hematology, Cary, N.C., which is affiliated with Duke University Hospital.

Space for the event is limited, therefore, a reservation is required. Institutional investors and analysts who would like to attend the event please contact David Burke at dburke@rigel.com.

A live webcast of the event, with accompanying slides, will be accessible by visiting the "Investors" section of the company's website at https://ir.rigel.com. A replay of the webcast will also be available and archived on the site.

About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. Rigel's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy. In addition, Rigel has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics.

Please see www.TAVALISSE.com for full Prescribing Information.

Contact: David Burke
Phone: 650.624.1232
Email: dburke@rigel.com

Rigel Pharmaceuticals Logo (PRNewsfoto/Rigel Pharmaceuticals, Inc.)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/rigel-to-host-investor--analyst-day-in-new-york-city-on-october-4-2018-300719972.html

SOURCE Rigel Pharmaceuticals, Inc.